Compugen LtdCGEN
Price (close)
$2.38
Market cap
$225.0M
P/E
6.4x
Revenue (FY)
$72.8M
Net income
$35.3M
Dividend yield
—
1-year total return
72.5%
Net margin
48.6%
Revenue growth
161.1%
Debt / equity
—
What Compugen Ltd does.
our AI/ML powered computational discovery platform, to identify novel drug targets and to develop therapeutics in the field of cancer
immunotherapy. Our innovative immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig and GS-0321
(previously COM503). COM701, a potential first-in-class anti-PVRIG antibody, and COM902, a potential best-in-class therapeutic anti-TIGIT
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $2.0M | $6.0M | $7.5M | $33.5M | $27.9M | $72.8M |
| Net income | -$29.7M | -$34.2M | -$33.7M | -$18.8M | -$14.2M | $35.3M |
| Free cash flow | -$28.5M | -$23.0M | -$34.6M | -$36.1M | $49.5M | $31.3M |
More on CGEN.
- Compugen Ltd summary
- Compugen Ltd financial statements
- Compugen Ltd key metrics
- Compugen Ltd health scores and style box
- Compugen Ltd earnings
- Compugen Ltd dividends
- Compugen Ltd valuation
- Compugen Ltd ownership and insiders
- Compugen Ltd peers
Figures from Compugen Ltd's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.